Press release
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Outlook Report 2024 (Updated)
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline
Key Takeaways from the Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Report
• DelveInsight's Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Human Immunodeficiency Virus Type 1 (HIV-1) Infection treatment.
• The leading companies working in the Human Immunodeficiency Virus Type 1 (HIV-1) Infection Market include United BioPharma, Gilead sciences, Taimed Biologics, Merck Sharp & Dohme, Janssen Sciences, CytoDyn Biosciences, MacroGenics, and others.
• Promising Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Therapies in the various stages of development include B/F/TAF, TDF/3TC/EFV, ISL, DOR, Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC), Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), MK-8591A, and others.
• April 2024: ST Pharma Co. Ltd- A Phase 2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Investigate the Antiviral Effect, Safety, Tolerability, and Pharmacokinetics of STP0404 in Treatment-Naïve Adults With HIV-1 Infection.
• April 2024: Merck Sharp & Dohme LLC- A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study.
• April 2024:- Gilead Sciences- An Umbrella Phase 1b, Open-label, Multi-Cohort Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Novel Antiretrovirals in Participants With HIV-1.
Request a sample and discover the recent advances in Human Immunodeficiency Virus Type 1 (HIV-1) Infection Treatment Drugs @ Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Report- https://www.delveinsight.com/sample-request/human-immunodeficiency-virus-hiv-1-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Human Immunodeficiency Virus Type 1 (HIV-1) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Overview
HIV-1 is the most common type of Human Immunodeficiency Virus. It attacks the body's immune system. The virus destroys CD4 cells. CD4 cells help the body to fight infections. HIV-1 can severely damage immune system and lead to Acquired Immune Deficiency Syndrome (AIDS). Infection with HIV type 1 (HIV-1) typically occurs across mucosal surfaces or by direct inoculation.
Find out more about Human Immunodeficiency Virus Type 1 (HIV-1) Infection Therapeutics Assessment @ Human Immunodeficiency Virus Type 1 (HIV-1) Infection Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/human-immunodeficiency-virus-hiv-1-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Emerging Drugs Profile
• UB421: United BioPharma
• Islatravir (MK-8591): Merck Sharp & Dohme
• PRO140: CytoDyn Inc.
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Human Immunodeficiency Virus Type 1 (HIV-1) Infection. The Human Immunodeficiency Virus Type 1 (HIV-1) Infection companies which have their Human Immunodeficiency Virus Type 1 (HIV-1) Infection drug candidates in the most advanced stage, i.e. phase III include, United Biopharma.
DelveInsight's Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Human Immunodeficiency Virus Type 1 (HIV-1) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Intramuscular
• Subcutaneous
• Molecule Type
Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Small molecule
• Product Type
Learn more about the emerging Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Therapies @ Human Immunodeficiency Virus Type 1 (HIV-1) Infection Clinical Trials Assessment- https://www.delveinsight.com/sample-request/human-immunodeficiency-virus-hiv-1-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Report
• Coverage- Global
• Human Immunodeficiency Virus Type 1 (HIV-1) Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Human Immunodeficiency Virus Type 1 (HIV-1) Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Human Immunodeficiency Virus Type 1 (HIV-1) Infection Companies- United BioPharma, Gilead sciences, Taimed Biologics, Merck Sharp & Dohme, Janssen Sciences, CytoDyn Biosciences, MacroGenics, and others.
• Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Therapies- B/F/TAF, TDF/3TC/EFV, ISL, DOR, Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC), Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), MK-8591A, and others.
Dive deep into rich insights for new drugs for Human Immunodeficiency Virus Type 1 (HIV-1) Infection Treatment, Visit @ Human Immunodeficiency Virus Type 1 (HIV-1) Infection Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/human-immunodeficiency-virus-hiv-1-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Human Immunodeficiency Virus Type 1 (HIV-1) Infection - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Collaboration Deals
9. Late Stage Products (Phase III)
10. UB421: United BioPharma
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. PRO140: CytoDyn Inc.
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Key Companies
20. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Key Products
21. Human Immunodeficiency Virus Type 1 (HIV-1) Infection- Unmet Needs
22. Human Immunodeficiency Virus Type 1 (HIV-1) Infection- Market Drivers and Barriers
23. Human Immunodeficiency Virus Type 1 (HIV-1) Infection- Future Perspectives and Conclusion
24. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Analyst Views
25. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Key Companies
26. Appendix
For further information on the Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline therapeutics, reach out to Human Immunodeficiency Virus Type 1 (HIV-1) Infection Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/human-immunodeficiency-virus-hiv-1-infection-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
https://www.bestadsontv.com/profile/462518/Denny-Dones
https://manybooks.net/user/denny-dones
https://topbazz.com/germanydennydones
https://wibki.com/dennydones1
https://onlineghibli.com/tavern/members.php?mode=profile&userid=12548&boardid=1
https://www.undrtone.com/germanydennydon
https://solo.to/germanydennydones
https://app.geniusu.com/users/2455075
https://forum.alidropship.com/members/germanydennydones.50354/#about
https://pantip.com/profile/7306022#topics
https://pubhtml5.com/homepage/npvs/preview
https://doodleordie.com/profile/germanydennydones
https://www.rafabasa.com/author/germanydennydones/
https://www.tabletennisdaily.com/forum/members/germanydennydones.122613/#about
https://nhattao.com/members/user6331540.6331540/
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Outlook Report 2024 (Updated) here
News-ID: 3465768 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for HIV
HIV Drugs Market - Defeating HIV Together: Advancing Treatment Options for a Bri …
Newark, New Castle, USA: The "HIV Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
HIV Drugs Market: https://www.growthplusreports.com/report/hiv-drugs-market/7792
This latest report researches the industry structure, sales, revenue,…
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments
Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV…
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine
Need for the Development of HIV Vaccine
Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus
HIV Vaccine Development Process
4.1 Introduction
…
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways…
